A study led by researchers at the Hospital del Mar Research Institute advances one of the most significant milestones in breast cancer treatment, making immunotherapy effective against the most common tumor type, estrogen receptor-positive or luminal breast cancer.
A new study reveals that a rarely-diagnosed and frequently drug-resistant species, Aspergillus tubingensis, may be one of the most common causes of fungal infections in Southern California.
Leon Bellan, associate professor of mechanical and biomedical engineering at Vanderbilt, and his team have developed a novel cooling-triggered device that could allow patients to safely and conveniently receive drugs for pain relief.
Researchers have built a tiny, lightweight microscope that captures neuron activity with unprecedented speed that can be used in freely moving animals. The new tool could give scientists a more complete view of how brain cells process information during natural behavior.
A new study led by researchers at York University shows that dance can be beneficial in halting the cognitive decline associated with Parkinson’s disease and, for some participants, they even showed signs of improvement.
Learn how axolotls are able to fully regenerate their thymus, a small organ that trains immune cells to fight infections.
CAESAREA, Israel, Dec. 5, 2025 /PRNewswire/ — IceCure Medical Ltd. (NASDAQ: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced it received a Notice of Allowance for a patent from the China National Intellectual Property Administration for its invention titled “Cryogen Flow Control” which relates to its next-generation XSense™ cryoablation system and probes.
A genetic variant is likely putting some children suffering with myocarditis—inflammation of the heart muscle—at higher risk of developing heart failure, which can be fatal, according to a study published in Circulation Heart Failure.
A team led by Professor Hui Wei, a pioneer in nanozyme research at Nanjing University, has unveiled an ultrasmall theranostic nanozyme with the potential to transform the diagnosis and treatment of abdominal aortic aneurysm (AAA)—a highly lethal vascular disease with limited therapeutic options.
Tiny immune cells called microglia protect the central nervous system (CNS) in a multitude of ways: They provide innate immunity, shape neurodevelopment, maintain homeostasis and modulate neurological disorders. That functionality can be lost, however, when microglia acquire mutations.